Paper Details

  1. Home
  2. Paper Details

Clinical activity of brigatinib in ROS1-rearranged non-small cell lung cancer.

Author: , AgbaryaA, BarJ, CyjonA, DudnikE, GrinbergR, MoskovitzM, PeledN

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

A study of 10 patients with ROS1-rearranged advanced non-small cell lung cancer (NSCLC) treated with brigatinib found that three patients demonstrated a partial response (ORR-37%). One crizotinib-naive patient had an ongoing response at 21.6 months. The drug demonstrated modest activity in crizotinib-resistant patients.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Brigatinib is a potent ROS1 inhibitor. The existing data on its clinical activity in ROS1-rearranged non-small cell lung cancer (NSCLC) are limited to four cases. METHODS: Six patients with ROS1-rearranged advanced NSCLC treated with brigatinib were identified through search of the inte...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1007/s12094-020-02376-w

データ提供：米国国立医学図書館（NLM）

The Clinical Activity of Brigatinib in ROS1-Rearranged NSCLC

This research delves into the field of [oncology] and focuses on the treatment of [ROS1-rearranged non-small cell lung cancer (NSCLC)], a specific type of [lung cancer]. The authors investigated the clinical activity of [brigatinib], a [potent ROS1 inhibitor], in patients with [ROS1-rearranged NSCLC]. The study analyzed data from [ten patients] and revealed [modest activity] of [brigatinib] in [crizotinib-resistant] patients, with an [objective response rate (ORR)] of [37%]. While [brigatinib] demonstrated promising results in some patients, the authors emphasize the need for further investigation, particularly in understanding its [intracranial and systemic activity] and its role in addressing [crizotinib resistance].

Brigatinib's Potential in ROS1-Rearranged NSCLC

The research showcases the potential of [brigatinib] as a treatment option for [ROS1-rearranged NSCLC]. The observed [objective response rate] in [crizotinib-resistant] patients is encouraging, suggesting that [brigatinib] may offer a new therapeutic avenue for these patients.

Future Directions in ROS1-Rearranged NSCLC Treatment

The authors highlight the need for further research to fully understand the [mechanisms] of [crizotinib resistance] and to determine the optimal use of [brigatinib] in treating [ROS1-rearranged NSCLC]. These efforts will ultimately lead to more effective and personalized treatments for patients with this challenging disease.

Dr. Camel's Conclusion

This study is like a desert prospector searching for a valuable mineral deposit. Just as a prospector needs to analyze the surrounding environment to identify the best resources, [oncologists] need to carefully understand the [molecular characteristics] of [lung cancer] to guide [treatment] decisions.

Date :
  1. Date Completed 2021-07-12
  2. Date Revised 2021-07-12
Further Info :

Pubmed ID

32462394

DOI: Digital Object Identifier

10.1007/s12094-020-02376-w

Related Literature

Article Analysis
・Effects of brigatinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.